The estimated Net Worth of Yezan Munther Haddadin is at least $35.5 mil dollars as of 28 March 2024. Mr. Haddadin owns over 1,881 units of Outlook Therapeutics Inc stock worth over $35,487 and over the last 7 years he sold OTLK stock worth over $0. In addition, he makes $0 as Independent Director at Outlook Therapeutics Inc.
Yezan has made over 5 trades of the Outlook Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,881 units of OTLK stock worth $22,233 on 28 March 2024.
The largest trade he's ever made was buying 33,343 units of Outlook Therapeutics Inc stock on 6 October 2022 worth over $43,012. On average, Yezan trades about 3,624 units every 71 days since 2017. As of 28 March 2024 he still owns at least 5,048 units of Outlook Therapeutics Inc stock.
You can see the complete history of Mr. Haddadin stock trades at the bottom of the page.
Yezan Munther Haddadin J.D. serves as Independent Director of the Company. From 2013 to 2014, Mr. Haddadin served as an Advisor at Ripplewood Holdings LLC, a New York-based private equity firm. Mr. Haddadin also served as a Managing Director at Perella Weinberg Partners in New York from 2007 to 2013 and an Executive Director with J.P. Morgan in its mergers and acquisitions group from 2000 to 2007. Mr. Haddadin holds a J.D. from Northwestern University Law School and a B.S. in Foreign Service from Georgetown University. Mr. Haddadin was initially appointed to fill a vacancy on our board and was designated for such vacancy by BioLexis Pte. Ltd., or BioLexis, pursuant to the Investor Rights Agreement by and between our company and BioLexis dated September 11, 2017, as amended from time to time, or the BioLexis IRA.
Yezan Haddadin is 44, he's been the Independent Director of Outlook Therapeutics Inc since 2018. There are 12 older and 1 younger executives at Outlook Therapeutics Inc. The oldest executive at Outlook Therapeutics Inc is Ralph H. Thurman, 72, who is the Independent Exec. Chairman.
Yezan's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830.
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv..., eVentures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include: